2Kalden J,SchattenkirehnerM,Sorellsen H,et al.Five yearfollow -up:efficacy and safety of leflumide in patientswith ae -tiverheumatlidarthritis[J].Arthritis Rheum,2001,44(9):173 - 176.
3Dimitrova P,Skapenko A,Schleyerbach R,et al.Im-muno -modu -latory functions of leflunomide:inhibition of T helper (Th) 1 cell activation and promotion of Th2 differentiation[J].ArthritisRheum,2001,44(1):216 -221.
5Chow K M,Szeto C C.Leflunomide and anti -glomerularbase -mentmembrane glomerulonephritis:commenton the letterbyBruyn[J].ArthritisRheum,2004,50(1):336-337.
6Breedveld F C,Dayer J M.Leflunomide:mode of action in thetreatment of rheumatoid arthritis[J].Ann Rheum Dis,2000,59:841 -849.
7Tam L S,Li EK,Wong C K,et al.Double -blind,randomized,placebo -controlled pilot study of leflunomide in systemic lupuserythematosus[J].Lupus,2004,13:601 -604.
8Smolen J S,Kalden J R,Scott D L,et al.Efficacy and safety ofleflunomide compared with placebo and sulphasalazine in activerheumatoid arthritis:a double -blind,randomised,multicentretria.lEuropeanLeflunomideStudyGroup[J].Lancet,1999,353:259 - 266.
9Kalden J R,Schattenkirchner M,SorensenH,et al.The efficacy andsafety of leflunomide in patients with active rheumatoid arthritis:afire -year followupstudy[J].ArthritisRheum,2003,48:1 513-1 520.
